Compass Therapeutics Stock Price Drops 7.6%

Biotech firm's shares decline amid broader market volatility

Apr. 17, 2026 at 9:58pm

Got story updates? Submit your updates here. ›

An extreme close-up of complex, metallic biotech laboratory equipment and machinery, conveying a sense of industrial power and scientific innovation.Compass Therapeutics' cutting-edge biotech equipment reflects the company's commitment to advancing cancer immunotherapies.Cambridge Today

Shares of Compass Therapeutics (NASDAQ:CMPX), a clinical-stage biotech company focused on immuno-oncology therapies, fell 7.6% during Friday's trading session. The stock traded as low as $6.13 before closing at $6.03, with trading volume down 45% from the average. The decline came amid broader market volatility, though the company's fundamentals remain strong with several promising drug candidates in development.

Why it matters

Compass Therapeutics is a closely watched biotech firm due to its innovative pipeline of cancer immunotherapies. The stock's performance is closely tied to investor sentiment around the company's clinical trial progress and regulatory milestones. This dip, while significant, is likely part of normal market fluctuations rather than a reflection of any major issues with the company's operations or outlook.

The details

The 7.6% drop in Compass Therapeutics' stock price on Friday was driven by a broader sell-off in the biotech sector. The company's lead programs include the bispecific antibody CTX-471, which targets the PD-1 and PD-L1 checkpoints, and DSP107, a CD47-SIRPα pathway modulator. While the stock has experienced volatility, Wall Street analysts remain largely bullish, with a 'Moderate Buy' consensus rating and an average price target of $14.20.

  • Compass Therapeutics stock closed at $6.53 on Thursday, April 16, 2026.
  • On Friday, April 17, 2026, the stock traded as low as $6.13 and closed at $6.03, down 7.6% for the day.

The players

Compass Therapeutics, Inc.

A clinical-stage biotechnology company dedicated to developing novel immuno-oncology therapies, headquartered in Cambridge, Massachusetts.

Wall Street Zen

A research firm that upgraded Compass Therapeutics from a 'sell' rating to a 'hold' rating in February 2026.

Guggenheim

An investment bank that reiterated a 'buy' rating and $12 price target on Compass Therapeutics in March 2026.

Craig Hallum

An investment firm that initiated coverage on Compass Therapeutics with a 'buy' rating and $15 price target in February 2026.

Canaccord Genuity Group

An investment bank that set a $13 price target on Compass Therapeutics in February 2026.

Raymond James Financial

A financial services firm that reiterated an 'outperform' rating on Compass Therapeutics in March 2026.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

This stock price decline appears to be a temporary market fluctuation rather than a fundamental issue with Compass Therapeutics' business. The company's promising pipeline of cancer immunotherapies and positive analyst sentiment suggest the long-term outlook remains favorable, though investors should expect continued volatility in the biotech sector.